MP35-15 DEVELOPMENT AND VALIDATION OF A NOVEL PROGNOSTIC MODEL FOR PREDICTING OVERALL SURVIVAL IN TREATMENT NAIVE CASTRATION-SENSITIVE METASTATIC PROSTATE CANCER.
Shusuke Akamatsu(Kyoto University), Osamu Ogawa(Kyoto University Hospital), Toshinari Yamasaki(Kyoto University Hospital), Tomonori Habuchi(Akita University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Norihiko Tsuchiya(Yamagata University), Naoki Terada(Kyoto University), Masashi Kubota(Kyoto University), Shintaro Narita(Akita University), Kei Mizuno(Dana-Farber Cancer Institute), Shigeto Ishidoya(Sendai City Hospital), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Takahiro Inoue(Mie University), Senji Hoshi, Takashi Kobayashi, Chikara Οhyama(Hirosaki University), Yoichi Arai(Japan Atomic Energy Agency), Toshihiko Sakurai(Sojo University), Takayuki Goto(Kyoto University), Masahiro Takahashi(Tohoku University), Satoshi Morita(Kyoto University), Shingo Hatakeyama(Hirosaki University), Ryuji Uozumi(Kyoto University), Keiji Ogura(The University of Tokyo), Masanori Ishida(Iwate Prefectural Central Hospital)
Cited by 0
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k